Research programme: anti-cancer therapeutics - ConverGene

Drug Profile

Research programme: anti-cancer therapeutics - ConverGene

Alternative Names: CG-223; CG-250

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ConverGene
  • Developer ConverGene; University of Maryland School of Medicine; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Ovarian cancer; Solid tumours

Most Recent Events

  • 18 Sep 2017 Preclinical trials in Ovarian cancer in USA (PO)
  • 05 Apr 2017 ConverGene establishes CRADA with the National Institute of Neurological Disorders and Stroke for the development of anti-caner therapeutics
  • 25 Jan 2017 ConverGene and University of Maryland agree to co-develop CG 223 and CG 250 in USA for Acute myelogenous leukemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top